%0 Journal Article
%T Factors Associated With the Improved Survival of Head and Neck Neuroblastomas Compared to Other Body Sites
%A Jessica R. Levi
%A Matthew R. Kaufmann
%A P. Ryan Camilon
%A Tyler A. Janz
%J Annals of Otology, Rhinology & Laryngology
%@ 1943-572X
%D 2019
%R 10.1177/0003489418818586
%X To examine pediatric neuroblastoma survival and management in the head and neck compared to other body sites. Retrospective analysis of a large population database. Patients in the Surveillance, Epidemiology, and End Results (SEER) database with neuroblastoma, NOS; ganglioneuroblastoma; or olfactory neuroblastoma diagnosed from birth to 18 years between 1973 and 2014 were included. These patients were classified into 1 of 3 categories based on primary tumor site: head and neck, adrenal, and ¡°other.¡± Four thousand five hundred neuroblastoma cases were identified. One hundred seventy-five (3.9%) occurred in the head and neck, 1,934 (43.0%) occurred in the adrenal gland, and 2,391 (53.1%) occurred in ¡°other¡± sites. The mean age at diagnosis was 4.21 years in the head and neck, 2.23 years in the adrenal gland, and 2.47 years in the ¡°other¡± cohorts (P < .001). Two- and 5-year disease-specific survival rates were 89% and 84% in the head and neck versus 77% and 65% in the adrenal and 84% and 77% in the ¡°other¡± cohorts (P < .001). The risk of disease-specific death (DSD) was higher in the adrenal cohort (adjusted hazard ratio [aHR] = 2.85; 95% CI, 1.54-5.27) compared to the head and neck cohort. Patients treated with surgery only had the lowest risk of DSD (aHR = 0.22; 95% CI, 0.13-0.35) compared to all other studied treatments. Our results demonstrate that primary neuroblastoma of the head and neck has a better prognosis than primary neuroblastoma of the adrenal gland
%K head and neck neoplasms
%K miscellaneous
%K outcome studies
%K overall survival
%K pediatric otolaryngology
%K treatment of head and neck tumors
%U https://journals.sagepub.com/doi/full/10.1177/0003489418818586